World-first clinical trial for treating spinal cord injury
A Phase I human clinical trial is set to commence to test the efficacy and safety of the transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury.
A Phase I human clinical trial is set to commence to test the efficacy and safety of the transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury.
Native Charge Detection Mass Spectrometry will enable cross-collaboration research to develop life-changing therapies, vaccines and diagnostics.
Griffith to partner with Blackmore Family Foundation, paving the way for world-class business leadership in Australia.
We’re excited to announce the launch of the Bourne Foundation Nuclear Magnetic Resonance (NMR) Facility, an institute core facility that...
Griffith University’s Institute for Glycomics has received a $5 million philanthropic donation from the International Leducq Foundation to further the development of a Strep A vaccine.
Griffith University’s world-first study into cell transplantation to repair injuries to the nervous system has received a major boost thanks to a $5.4 million funding extension from the MAIC.
Discovery of stone tools and cut-marked animal bones in Kenya offers window into the dawn of stone technology.
World-first data analysis platform, EcoCommons has been launched, transforming our ability to understand the impacts of the climate crisis on Australia’s environment and native species.
Study suggests COVID-19 could be a potential trigger for ME/CFS.
Institute for Glycomics researchers receive funding boost in their fight against cancer with $2.6 million awarded by the Australian Cancer Research Foundation.